Business

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1802 Injection Indicated for Adolescent Seasonal Allergic Rhinitis

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1802 Injection Indicated for Adolescent Seasonal Allergic Rhinitis

articleChongqing Genrix Biopharmaceutical Co., Ltd. Class AAugust 19, 20253/news/announcement-on-voluntary-disclosure-of-obtaining-notice-of-approval-for-drug-clinical-trial-of-gr1802-injection-indicated-for-adolescent-seasonal-allergic-rhinitis
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1802 Injection Indicated for Adolescent Seasonal Allergic Rhinitis

About this update from Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1802 Injection Indicated for Adolescent Seasonal Allergic RhinitisThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Chongqing Genrix Biopharmaceutical Co., Ltd. Class A